Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy

Breast Cancer Research and Treatment

Volumn 59, Issue 2, 2000, Pages 171-175

  Gregory, R K ^a   Powles, T J ^a   Salter, J ^b   Chang, J C ^a   Ashley, S ^a   Dowsett, M ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

CerbB2; Chemotherapy; Neoadjuvant; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; METHOTREXATE; MITOXANTRONE; ONCOPROTEIN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; ADJUVANT THERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROTO ONCOGENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS;

EID: 0033625423     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006394317282     Document Type: Article

References (27)

1. 1. Early breast cancer triallists collaborative group systemic treatment of early breast cancer. Lancet 339: 1-15, 71-84, 1990
2. 2. Powles TJ, Hickish TF, Makris A, et al.: Randomised trial of chemoendocrine therapy starting before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552, 1995
3. 3. Bonadonna G, Veronesi U, Brambilla C, et al.: Primary chemotherapy to avoid mastectomy in tumours with diameters of 3 cm or more. J Natl Cancer Inst 82: 1539-1545, 1990
4. 4. Fisher B, Brown A, Mamaounas E, et al.: Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from NSABP-18 JCO 15: 2483-2493, 1997
5. 5. Fisher B, et al.: Presence of a growth stimulating factor in serum following primary tumour removal in mice. Cancer Res 49: 1996-2001, 1989
6. 6. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-180, 1987
7. 7. Hourguchi J, Iino Y, Takei H, et al.: Immunohistochemical study on the expression of CerbB2 oncoprotein in breast cancer. Oncology 51: 47-51, 1994
8. 8. Walker RA, Gullick WJ, Varley JM: An evaluation of immuno-reactivity for CerbB2 protein as a marker of poor short term prognosis in breast cancer. Br J Cancer 60: 426-429, 1989
9. 9. Giai M, Roagna R, Ponzone R, et al.: Prognostic and predictive relevance of CerbB2 and ras expression in node-positive and negative carcinoma of the breast. Anticancer Res 14: 1441-1450, 1994
10. 10. Tandon AK, Clark GM, Chamness GC, et al.: HER2/neu oncogene, protein and prognosis in breast cancer.J Clin Oncol 7: 1120-1128, 1989
11. 11. Borg A, Tandon AK, Sigurdsson H, et al.: HER-2/neu amplification predicts poor survival in node positive carcinoma of the breast. Cancer Res 50: 4332-4337, 1990
12. 12. Thor AD, Schwartz LH. Koerner FC, et al.: Analysis of CerbB2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147-7152, 1989
13. 13. Ottestad L, Andersen TI, Nesland JM, et al.: Amplification of CerbB2 in node negative carcinoma of the breast and relation to prognosis. Acta Oncol 32(3): 89-294, 1993
14. 14. Gasparini G, Gullick WJ, Maluta S, et al.: CerbB3 and CerbB2 protein expression in node negative carcinoma of the breast -an immunocytochemical study. Eur J Cancer 30(A): 16-22, 1994
15. 15. Rosen et al.: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 75: 1320-1326, 1995
16. 16. Van de Vijver M, Bersselaar R, Devilee P, et al.: Amplification of neu oncogene in human mammary tumours is relatively frequent and is often accompanied by umplifiaction of the linked Cerb A oncogene. Mol Cell Bio 2019-2023, May 1987
17. 17. Ji H, Lipponen P, Aaltomaa S, et al.: CerbB2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 13: 1147-1152, 1993
18. 18. Wright C, Nicholson S, Angus B, et al.: Relationship between CerbB2 protein product expression and response to therapy in advanced breast cancer. Br J Cancer 65: 118-121, 1992
19. 19. Gusterson BA, Gelber RD, Goldhirsch A, et al.: Prognostic importance of CerbB2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992
20. 20. Allred DC, Clark GM, Tandon AK, et al.: HER-2/neu in node negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol 10: 599-605, 1992
21. 21. Muss HB, Thor AD, Berry DA, et al.: CerbB2 expression and response to adjuvant therapy in women with node positive early breast cancer. N Engl Med 330: 1260-1261, 994
22. 22. Makris A, Powles TJ, Allred DC, et al.: Predicting response to neoadjuvant chemo-endocrine therapy in primary breast carcinoma. Cancer Res Treat 37(s): 35, 1996
23. 23. Gullick WJ, Love SB, Wright C, et al.: CerbB2 protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991
24. 24. Winstanley I, Cooke T, Murray GD, et al.: The long term prognostic significance of CerbB2 in primary breast cancer. Br J Cancer 63: 447-450, 1991
25. 25. Barnes DM, Lammie GA, Mills RR, et al.: An immunohistochemical evaluation of CerbB2 expression in human breast cancer. Br J Cancer 58: 448-452, 1988
26. 26. Carlomagno C, Perrone F, Gallo C, et al.: CerbB2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without lymph node metastases. JCO 14: 2702-2708, 1996
27. 27. Clahsen PC, Van de Velde C, Duval C, et al.: p53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node negative breast cancer. JCO 16(2): 470-474, 1998